Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Intratumoral CpG, ibrutinib and radiotherapy in low-grade R/R follicular lymphoma

Tanaya Shree • 2 Jul 2019
ICML 2019
B-Cell Lymphoma Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma Ibrutinib SD-101

Tanaya Shree, MD, Stanford University Medical Center, California, CA, discusses the interim clinical and correlative results of the Phase I/II trial of the CpG TLR9 agonist SD-101, ibrutinib and radiation therapy in relapsed/refractory low-grade follicular lymphoma (NCT02927964). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Tanaya Shree

3:04
Impaired immunity in DLBCL survivors
Tanaya Shree • 2 Jul 2019

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals